Sponsored Links

Cerenis Therapeutics And Novasep Awarded 10.7M Euros Funding From The French Government For The Development CER-001, An HDL Mimetic PDF Print E-mail
Medical News - Heart Disease
Cerenis Therapeutics SA (Cerenis), a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and other metabolic diseases, and Groupe Novasep (Novasep), a leading supplier of manufacturing solutions to the life sciences industries, announce today that they have received French Government funding through OSEO to finance the dev...

Read more: Heart Disease News From Medical News Today